Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear Medicine and Molecular Imaging.
June 22, 2023
· 7 min read